Board Update

RNS Number : 7086D

Feedback PLC

30 June 2021

 

Feedback plc

Board Update

London, 30 June 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that Simon Sturge has resigned as a Non-Executive Director of the Company to focus on his other commitments.

Rory Shaw, Chairman of Feedback, commented:

"We would like to thank Simon for his significant and valuable contributions over the past three years.  Simon has brought tremendous experience, guidance and insight to the Board and he leaves with Feedback in a stronger position than ever.  We wish him well for the future."

Simon Sturge, added:

"I have really enjoyed my time on the Board of Feedback and I believe that the Company is entering into a really exciting phase in its continued development."

Enquiries:

Feedback plc Tom Oakley, CEO Feedback media: Nick Mayhew, Chief Marketing Lead	[phone] [e-mail] [phone]
Allenby Capital Limited (Nominated Adviser) David Worlidge / Vivek Bhardwaj	[phone]
Peterhouse Capital Limited (Joint Broker) Lucy Williams / Duncan Vasey	[phone]
Stanford Capital Partners Limited (Joint Broker) Patrick Claridge / John Howes	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus/Nick Rome/Nicholas Johnson	07980 541 893 or 07748 325 236 or 07884 664 686

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

END

 

 

BOAFLFFSRTIIVIL